Zheng Quan Ri Bao·2026-01-27 23:28Core Viewpoint - The company, Jiangsu Sihuan Bioengineering Co., Ltd., is expected to report a negative net profit for the fiscal year 2025, following a financial warning due to previous losses and low revenue [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a net profit in the range of -46 million to -33 million yuan, with revenue expected to be between 330 million and 350 million yuan [4][18]. - The forecast data is based on preliminary calculations by the company's finance department and has not been audited by an accounting firm [2][5]. Group 2: Reasons for Performance Changes - The increase in revenue is primarily attributed to significant growth in seedling sales from the wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd. [3]. - The reduction in net losses is due to decreased asset impairment losses and operating expenses, as well as improved cost control by the subsidiary, Beijing Sihuan Biopharmaceutical Co., Ltd. [3]. Group 3: Risk of Delisting - The company's stock will be subject to delisting risk warnings starting April 30, 2025, due to a negative audited net profit and revenue below 300 million yuan for the fiscal year 2024 [4][10]. - If the company fails to meet certain financial criteria in the 2025 annual report, it may face termination of its stock listing [10][17].